Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 5/20 | 0.49 |
| ▸ | HTR1B | P28222 | 5/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11544472 | 0.91 | RAB9A (0.70) | RAB9ASMN1; SMN2HTR2AMEN1LMNA | |
| SCHEMBL30274876 | 0.86 | RAB9A (0.70) | RAB9ASMN1; SMN2HTR2AMEN1LMNA | |
| SCHEMBL11538702 | 0.86 | RAB9A (0.70) | RAB9ASMN1; SMN2HTR2AMEN1LMNA | |
| SCHEMBL11536718 | 0.86 | RAB9A (0.70) | RAB9ASMN1; SMN2HTR2ATRPM8CDK4 | |
| SCHEMBL11536860 | 0.83 | HTR2A (0.68) | RAB9ASMN1; SMN2HTR2ATRPM8MEN1 | |
| SCHEMBL10679736 | 0.79 | RAB9A (0.92) | RAB9ASMN1; SMN2HTR2AMEN1MAPT | |
| SCHEMBL11543826 | 0.79 | RAB9A (0.70) | RAB9ASMN1; SMN2HTR2AMEN1LMNA | |
| SCHEMBL11539493 | 0.79 | RAB9A (0.70) | RAB9ASMN1; SMN2HTR2AGPR84MPO | |
| SCHEMBL11538262 | 0.79 | SMN1; SMN2 (0.63) | RAB9ASMN1; SMN2HTR2AMAPTHTR1D | |
| SCHEMBL26508389 | 0.78 | MPO (0.67) | HTR2ATRPM8CDK4CCND1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105666-A1 | TRIAZABENZO (A)NAPHTHO(2,1,8-CDE) AZULENE COMPOUNDS. | LES LABORATOIRES SERVIER (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | LES LABORATOIRES SERVIER (FR) | 2009-12-03 | — | — | US | disclosed |
| US-5332748-A | Antiischemic, antianoxic | ROUSSEL-UCLAF (FR) | 1994-07-26 | — | — | US | disclosed |
| US-5093337-A | SUBSTITUTED DERIVATIVES OF 20,21-DINOREBURNAMENINE, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL UCLAF (FR) | 1992-03-03 | — | — | US | disclosed |
| US-4138489-A | FORMALDEHYDE, QUATERNIZATION | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105666-A1 | TRIAZABENZO (A)NAPHTHO(2,1,8-CDE) AZULENE COMPOUNDS. | NR1I2, NR2E1, NR0B2 | RAB9A 1612/4885SMN1; SMN2 3404/4885HTR2A 231/4885 |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | NLN, GAP43, SNCA | RAB9A 2647/4885SMN1; SMN2 5/4885HTR2A 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.